Rafarma Pharmaceuticals(OTC) RAFA

Rafarma Pharmaceuticals, Inc. is a diversified pharmaceutical enterprise focused on manufacturing and distributing a variety of medicinal products, primarily within the Russian market. The company specializes in generic antibiotics, anti-cancer medications, and innovative treatments, including medical cannabis products.

Products and Services

• Generic antibiotics and specialized drugs
• Anti-cancer medications and cephalosporin-derived compounds
• Medical cannabis suppositories for inflammatory bowel disease

Growth Outlook

• Recent quarterly revenue reached $278,000, showing potential for growth
• Strong gross profit margin of 42.8% in the latest quarter
• Expansion into medical cannabis products may drive future revenue

Financial Highlights

• Trailing twelve months (TTM) revenue of $8.57 million
• Net income of $74,000 reported in the latest quarter
• Operating income margin of 29.5% indicates operational efficiency

Rafarma Pharmaceuticals, Inc. operates in the healthcare sector, specifically within the drug manufacturing industry, focusing on specialty and generic medications. The company has a robust product portfolio that includes a range of antibiotics and innovative treatments, positioning it well within the growing pharmaceutical market. The recent quarterly performance indicates a positive trend, with a notable gross profit margin and a solid operating income margin, reflecting effective cost management and operational efficiency. The company's foray into medical cannabis products represents a strategic move to diversify its offerings and tap into emerging markets. Overall, Rafarma Pharmaceuticals, Inc. presents a compelling opportunity for investors interested in the pharmaceutical sector, particularly in the context of its growth potential and recent financial performance.